Eptifibatide induced profound thrombocytopenia in a patient with pelvic malignancy: A case report

Squires, Kathryn C.; Guntupalli, Saketh R.; Thaker, Premal H.

doi:10.1016/j.gynor.2012.03.002

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eptifibatide is a synthetic cyclic heptapeptide which functions via competitive inhibition of the platelet GPIIb/IIIa receptor, thereby preventing fibrinogen-platelet aggregation, a precipitant of thrombus formation [ 9 ]. Thrombocytopenia is a well-documented adverse effect associated with the use of eptifibatide in the setting of both ACS and as prophylaxis against stent restenosis in patients with malignancy [ 5-9 ].…”

Section: Discussionmentioning

confidence: 99%

“…Despite these benefits, many case reports have demonstrated clinically significant side effects of GPIIb/IIIa inhibitor use, the most notable of which is thrombocytopenia [ 5-7 ]. Two recent case reports have further demonstrated thrombocytopenia accompanied with disseminated intravascular coagulation (DIC) and/or thrombosis in patients administered eptifibatide [ 8 , 9 ]. Others have reported acute profound thrombocytopenia [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Eptifibatide and Cirrhosis: Rethinking GPIIb-IIIa Inhibitors for Acute Coronary Syndrome in the Setting of Liver Dysfunction

et al. 2014

View full text Add to dashboard Cite

Glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors, such as eptifibatide, are routinely used in the setting of acute coronary syndrome (ACS) prior to or during percutaneous coronary intervention (PCI). While numerous studies have demonstrated improved clinical outcomes with eptifibatide use, adverse effects including thrombocytopenia have also been noted. For this reason, patients with baseline thrombocytopenia or liver disease should be cautiously evaluated prior to drug administration. Here we report a case of acute profound and prolonged eptifibatide-induced thrombocytopenia in a patient with cirrhotic liver dysfunction. We propose and discuss the need for a risk stratification tool to be established for identifying which patients with ACS in the setting of chronic liver disease receive GPIIb/IIIa inhibitors.

show abstract

Section: Discussionmentioning

confidence: 99%